Gastroenterology IBD denials: appealing biologic step-therapy and reauthorization

Denials of biologics for Crohn's disease and ulcerative colitis — anti-TNFs, anti-integrins, anti-IL-23s, and JAK inhibitors — are usually step-therapy or reauthorization denials, not judgments on the medicine. The proof a plan wants is typically already in the chart: prior therapy and response, disease activity, and the clinical rationale. The distinctive challenge is the reauthorization treadmill — the same approval is re-litigated every renewal cycle.

Why these denials happen

Plans gate IBD biologics with step therapy (a documented trial of conventional therapy first), prior authorization tied to disease severity, and periodic reauthorization. The clinical case usually meets guideline criteria — the AGA's care pathways support biologics for moderate-to-severe disease and earlier use in higher-risk patients — but the denial fires when the documentation isn't mapped to the plan's specific criteria, or when a reauthorization doesn't re-establish ongoing necessity and response.

The common denials

• Step therapy: a required conventional therapy (steroids, immunomodulators) wasn't documented as tried or contraindicated.
• Prior authorization criteria for disease severity or extent not established in the record.
• Reauthorization denied — ongoing response or continued medical necessity not re-documented.
• Off-label or non-preferred agent without the rationale for choosing it.
• Dose escalation or interval shortening not justified against the plan's criteria.

Is it worth appealing?

How to appeal

1. 1

   Document the step-therapy trail

   Show the trial, failure, intolerance, or contraindication of the conventional therapies the plan requires — a documented contraindication counts as a satisfied step.

2. 2

   Map severity to the criteria and the guideline

   Tie disease activity and extent to the plan's prior-auth criteria and the AGA care pathway for moderate-to-severe disease.

3. 3

   For reauthorization, prove ongoing response

   Document the response to therapy and the clinical risk of stopping — the reauthorization is its own medical-necessity case, not a formality.

Frequently asked

Clinical-coverage patterns and guideline references are summarized for plain-language reference and vary by plan and payer policy. This is general information for clinicians and billing staff, not medical, legal, or coding advice — confirm against the governing coverage policy and the current guideline for each claim.